THERACRYF PLC (TCF) — Research and Development Update

Investor webinar replay

Replay transcript excerpt

Good morning, ladies and gentlemen and welcome to the Terra Creeve Capital Markets Day throughout today's presentation attendees online will be in listen only mode. Questions are encouraged they can be submitted at any time using the Q and a tab just situated on the right hand corner of your screen. Please simply type in your questions at any time and press send. The company may not be in a position to answer every question received during the meeting itself. However, the company can review all questions submitted today, and we'll publish those responses on the Investor Me company platform. Before we begin, we'd like to submit the following poll. And if you give that your kind attention, I'm sure the company would be most grateful. I'd now like to hand over to CEO, doctor Hugh Jones. Good morning. Good morning, everybody, and a very warm welcome to the first THERACRYF R and D Day. We're going to expose a lot of data. We encourage questions. There'll be several slots for questions during this morning's agenda. With me here in London, Doctor. Glenn Clark, our Chief Medical Officer Doctor. Helen Cullman, our Chief Business Officer and online is Tony Hynonen, our Chief Financial Officer and also our collaborators from the Erasmus Medical Centre in Rotterdam, are leading our academic collaboration on glioblastoma. We're sharing this venue today with a brewery who are announcing their annual results. So I suppose in a funny way, of the things we're trying to do is both add shareholder value through addictions, but in sort of opposite directions. So to move forward, we are a public company, as you all know, so the usual disclaimers apply. And I'll start with the mission of THERACRYF, and that is to do what a biotech company can do to build a drug development powerhouse in p...